Actionable insights straight to your inbox

Equities logo

Relevium Rolling Up the Health and Wellness E-Commerce Space

Save for a few players, the online retail space is actually quite fragmented, creating opportunities for consolidation.

In December, Relevium Technologies (RLV:TSXV) penned a binding letter of intent to acquire the assets of nutraceutical company BioGanix Ltd. for US$4.25 million. The transaction is expected to close in March. The purchase is the first for Relevium as part of a strategy to consolidate e-commerce assets in the health and wellness space and roll them out into different markets.

The company is meticulously looking for acquisitions. An ideal buyout candidate has at least one product being sold via one platform in one market. Aiming for this type of company aligns Relevium to build its brand and scale sales in an online retail market expected to generate US$523 billion in sales by 2020.

Forrester Research estimates that more than 206 million shoppers will be shopping online by that time. Industry stalwarts like Amazon (AMZN) and Alibaba (BABA) control the lion’s share of sales through their third-party seller platforms while Walmart (WMT) is attempting to make a push into the space with their 2016 acquisition of Other than that, though, the industry is extremely fragmented, including subsectors like the US$39 billion pain relief market.

Based upon these parameters, BioGanix was a near perfect business for Relevium to acquire. The company has more than two dozen marketed nutraceuticals being sold nearly exclusively in the U.S., primarily through and the BioGanix website.

At approximately US$4 million in annual revenue, the Houston-based company was small enough for Relevium to get financed quickly, yet big enough to have a meaningful, immediate impact for Relevium. Relevium, which is headquartered in Montreal, Canada, did not acquire any of the debt of BioGanix, only all the assets related to the BioGanix product line.

The acquisition also brings significant infrastructure for Relevium, including a contract manufacturing organization that can handle production, quality control and any necessary FDA oversight, among other things.

Operating exclusively online provides BioGanix with high margins and low costs. In the 12 months through September 2016, the company was profitable, with net earnings of US$1.3 million. This means that Relevium bought the company for about 3.1x earnings, arguably a good deal by just about any metric.

BioGanix will become a part of the Relevium E-Health Inc. unit, an umbrella company designated for consolidating e-commerce businesses focused on health and wellness products, including nutraceuticals, supplements and other paramedic products.

The company says it has identified and maintains a pipeline of acquisition targets with current estimated revenues of over $100 million. While it is difficult to estimate what portion of the pipeline will materialize in a transaction, Relevium says its leadership team will remain focused on an aggressive acquisition model over the next two years.

In the interest of full disclosure, we call the reader’s attention to the fact that, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

I’ve long said we are under-utilizing nuclear energy. This shouldn’t be controversial; nuclear has something for everyone.